Targeted chemo infusion plus immunotherapy shows promise for tough liver cancer

NCT ID NCT07282509

Not yet recruiting Disease control Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial is testing a new approach for people with advanced liver cancer whose first treatment stopped working. The study combines a targeted chemotherapy infusion (paclitaxel liposome) delivered directly into the liver artery with systemic drugs like immunotherapy and a targeted pill. About 116 participants will be enrolled to see if this combination is safe and effective at shrinking tumors and improving survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paclitaxel cationic liposome (HA131) infused into the liver artery, plus enlonstobart or pembrolizumab (immunotherapy) and lenvatinib (targeted therapy)
What this could lead to: If successful, this could offer a new second-line treatment option for people with advanced liver cancer, potentially shrinking tumors and extending survival.
What could go wrong: This is an early-phase trial (Ib/II) with only 116 participants, so results are preliminary. The combination therapy may cause significant side effects, and the benefit over existing treatments is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.